FDA withdraws coronavirus emergency use authorization for hydroxychloroquine

Hydroxychloroquine.
(Image credit: GEORGE FREY/AFP via Getty Images)

At the request of Gary Disbrow, the acting director of the Biomedical Advanced Research and Development Authority, the Food and Drug Administration on Monday withdrew emergency use authorizations for hydroxychloroquine and chloroquine related to coronavirus treatment.

The authorizations were controversial, as many skeptics believed they were made because President Trump had touted the malaria drugs as effective treatments against COVID-19, despite researchers concerns about potential heart-related side effects. Ultimately, after reviewing new information from large clinical trials, the FDA said it does not believe the drugs are likely "to produce an antiviral effect" against the novel virus.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.